DOI: 10.1128/AAC.02174-16
Article Information
PubMed
Published By
History
- Received October 10, 2016
- Returned for modification October 22, 2016
- Accepted October 31, 2016
- Published online January 24, 2017.
Copyright & Usage
Copyright © 2017 American Society for Microbiology.
All Rights Reserved
.
Article Versions
- Accepted Manuscript version (November 14, 2016).
- You are viewing the most recent version of this article.
Author Information
- Ching-Chi Leea,b,c,d,
- Jiun-Ling Wangc,d,
- Chung-Hsun Leed,
- Chih-Chia Hsiehe,
- Yuan-Pin Hungc,d,f,
- Ming-Yuan Hongd,e,
- Hung-Jen Tangg,h and
- Wen-Chien Koc,d
- aDivision of Critical Care Medicine, Department of Internal Medicine, Madou Sin-Lau Hospital, Tainan, Taiwan
- bGraduate Institute of Medical Sciences, College of Health Sciences, Chang Jung Christian University, Tainan, Taiwan
- cDepartment of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
- dDepartment of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
- eDepartment of Emergency Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
- fDepartment of Internal Medicine, Tainan Hospital, Ministry of Health and Welfare, Tainan, Taiwan
- gDepartment of Medicine, Chi-Mei Medical Center, Tainan, Taiwan
- hDepartment of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan, Taiwan
- Address correspondence to Hung-Jen Tang, 8409d1{at}gmail.com, or Wen-Chien Ko, winston3415{at}gmail.com.
Citation Lee C-C, Wang J-L, Lee C-H, Hsieh C-C, Hung Y-P, Hong M-Y, Tang H-J, Ko W-C. 2017. Clinical benefit of appropriate empirical fluoroquinolone therapy for adults with community-onset bacteremia in comparison with third-generation-cephalosporin therapy. Antimicrob Agents Chemother 61:e02174-16. https://doi.org/10.1128/AAC.02174-16 .
